Wealth Enhancement Trust Services’s Anavex Life Sciences AVXL Stock Holding History

Wealth Enhancement Trust Services’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$616	Buy	+238	New	+$704	﹤0.01%	1208

Other funds holding AVXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

PAM

PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wealth Enhancement Trust Services's AVXL Position: Q2 2026 in Review

Wealth Enhancement Trust Services opened a new position in Anavex Life Sciences (AVXL) in Q2 2026: 238 shares worth $616. The stake represents ﹤0.01% of the portfolio and ranks #1208 among its holdings.

108 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

Wealth Enhancement Trust Services held 238 shares of Anavex Life Sciences worth $616 as of Q2 2026.
Anavex Life Sciences was a new Wealth Enhancement Trust Services position in Q2 2026.
Anavex Life Sciences made up ﹤0.01% of Wealth Enhancement Trust Services's portfolio in Q2 2026, its #1208 holding.
108 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q2 2026, filed 15 Jul 2026.